From: Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
n (%) | P-Value | ||||
---|---|---|---|---|---|
Positive (n = 98) | Negative (n = 34) | Focal Positive (n = 5) | Total (n = 137) | ||
Age groups | |||||
≤ 30 years | 3(3.1) | 0(0) | 0(0) | 3(2.2) | 0.460 |
31–50 years | 59(60.2) | 16(47.1) | 3(60) | 78(56.9) | |
> 50 years | 36(36.7) | 18(52.9) | 2(40) | 56(40.9) | |
Tumor stage/tumor size | |||||
T1(≤2 cm) | 16(16.3) | 7(20.6) | 1(20) | 24(17.5) | 0.964 |
T2(2.1–5.0 cm) | 51(52) | 17(50) | 3(60) | 71(51.8) | |
T3(> 5.0 cm) | 31(31.6) | 10(29.4) | 1(20) | 42(30.7) | |
ki67 index groups | |||||
≤ 15% | 10(10.2) | 5(14.7) | 2(40) | 17(12.4) | 0.345 |
16–24% | 5(5.1) | 3(8.8) | 0(0) | 8(5.8) | |
25–44% | 29(29.6) | 11(32.4) | 2(40) | 42(30.7) | |
> 44% | 54(55.1) | 15(44.1) | 1(20) | 70(51.1) | |
Nodal Status | |||||
Positive | 42(42.9) | 15(44.1) | 2(40) | 59(43.1) | 1.000 |
Negative | 56(57.1) | 19(55.9) | 3(60) | 78(56.9) | |
Nodal Stage | |||||
No | 58(59.2) | 19(55.9) | 3(60) | 80(58.4) | 0.907 |
N1 | 17(17.3) | 8(23.5) | 2(40) | 27(19.7) | |
N2 | 9(9.2) | 3(8.8) | 0(0) | 12(8.8) | |
N3 | 14(14.3) | 4(11.8) | 0(0) | 18(13.1) | |
Histological Subtypes | |||||
IDC | 83(84.7) | 28(82.4) | 5(100) | 116(84.7) | 0.633 |
Papillary | 5(5.1) | 0(0) | 0(0) | 5(3.6) | |
Medullary | 1(1) | 0(0) | 0(0) | 1(0.7) | |
metaplastic | 8(8.2) | 5(14.7) | 0(0) | 13(9.5) | |
Mixed | 1(1) | 1(2.9) | 0(0) | 2(1.5) | |
Tumor Grade | |||||
Grade-I | 0(0) | 1(2.9) | 0(0) | 1(0.7) | 0.165 |
Grade-II | 11(11.2) | 7(20.6) | 0(0) | 18(13.1) | |
Grade-III | 87(88.8) | 26(76.5) | 5(100) | 118(86.1) | |
Lymhovascular Invasion | |||||
Present | 25(25.5) | 6(17.6) | 1(20) | 32(23.4) | 0.788 |
Absent | 73(74.5) | 28(82.4) | 4(80) | 105(76.6) | |
Perinodal extension | |||||
Present | 19(19.4) | 9(26.5) | 0(0) | 28(20.4) | 0.425 |
Absent | 79(80.6) | 25(73.5) | 5(100) | 109(79.6) | |
Triple Negative phenotype | |||||
Basal | 10(10.2) | 3(8.8) | 1(20) | 14(10.2) | 0.532 |
Non Basal | 88(89.8) | 31(91.2) | 4(80) | 123(89.8) |